3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Recruiting
2
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
31
Lymphoma
18
Lymphoma, Large B-Cell, Diffuse
17
Sarcoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Neoplasm Metastasis
10
Hodgkin Disease
9
Lymphoma, Non-Hodgkin
8
Recurrence
7
Prostatic Neoplasms
7
Neoplasms
7
Multiple Myeloma
7
Burkitt Lymphoma
7
Ovarian Neoplasms
6
Leukemia
6
Lymphoma, B-Cell
5
Fallopian Tube Neoplasms
5
Cardiotoxicity
5
Carcinoma, Hepatocellular
5
Urinary Bladder Neoplasms
4
Osteosarcoma
4
Liver Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Lymphoma, Follicular
3
Leukemia, Myeloid, Acute
3
Leukemia, Biphenotypic, Acute
3
Colonic Neoplasms
3
Waldenstrom Macroglobulinemia
2
Interventions
pazopanib
2
sapanisertib
1
TTI-621
1
Radiotherapy, Intensity-Modulated
1
Polymerase Chain Reaction
1
Neoadjuvant Therapy
1
Gene Expression Profiling
1
Doxorubicin
1
Blotting, Western
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Dermatofibrosarcoma
×
Doxorubicin
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts